Home > Recent News > ObamaCare’s affect on Biomedical Research

ObamaCare’s affect on Biomedical Research

A piece in The Scientist briefly highlights some of the consequences of the Court’s upholding of the Affordable Care Act a.k.a. ObamaCare.

The key provisions that have a bearing on the lives and work of biomedical researchers include the establishment of a streamlined US Food and Drug Administration pathway for the approval of generic versions of protein-based drugs, so-called biosimilars; the creation of a translational research initiative at the National Institutes of Health called the Cures Acceleration Network; the launch of the Physician Payment Sunshine Act, which would require pharmaceutical and device makers to disclose all payments greater than $10 to physicians, and a push to increase funding for comparative effectiveness research.

How this will play out in effective legislature the next several months will tell us.

Categories: Recent News
  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: